Disease Overview：Gastrinoma（GZM）
Gastrinoma is a rare neuroendocrine tumor (NET) that secretes excessive gastrin, primarily arising from the duodenum or pancreas. It is the most common cause of Zollinger–Ellison syndrome (ZES), characterized by severe peptic ulcer disease, gastroesophageal reflux, and chronic diarrhea due to gastric acid hypersecretion. Diagnosis relies on fasting serum gastrin levels, secretin stimulation testing, and advanced imaging—including somatostatin receptor scintigraphy (e.g., ⁶⁸Ga-DOTATATE PET/CT) and endoscopic ultrasound (EUS)—to localize tumors and assess metastatic burden. Approximately 60–70% of gastrinomas are sporadic; the remainder occur in association with multiple endocrine neoplasia type 1 (MEN1). Management is multidisciplinary: surgical resection remains the only curative option for localized disease, while somatostatin analogs (e.g., octreotide, lanreotide), proton pump inhibitors (PPIs), peptide receptor radionuclide therapy (PRRT), and targeted systemic therapies (e.g., everolimus) are employed for unresectable or metastatic cases. Prognosis varies significantly based on tumor size, grade (Ki-67 index), lymph node involvement, and distant metastases.
China offers distinct advantages for gastrinoma management: leading academic hospitals—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—house nationally certified Neuroendocrine Tumor Centers staffed by endocrinologists, oncologic surgeons, and nuclear medicine specialists with extensive experience in complex NET cases. These centers utilize cutting-edge diagnostics, including high-resolution EUS, next-generation sequencing for MEN1 mutation screening, and FDA- and NMPA-approved PRRT protocols. Five-year survival rates for localized gastrinoma exceed 90% in top-tier Chinese institutions, supported by robust clinical data published in journals like *Endocrine-Related Cancer* and *Journal of Clinical Endocrinology & Metabolism*. Treatment costs in China are typically 40–60% lower than in the U.S. or Western Europe, without compromising evidence-based standards—PPI regimens, surgical interventions, and PRRT are all delivered at internationally benchmarked quality. As a dedicated medical tourism agency, we facilitate seamless care for international patients: coordinating appointments with specialist teams, providing itemized, transparent pricing in advance, arranging visa support, accommodation, interpreter services, and post-treatment follow-up—all tailored to individual clinical and logistical needs.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown for Gastrinoma (Endocrinology Department)
Non-Surgical / Medical Management
*Indicated for unresectable, metastatic, or medically controlled disease; primary goal is acid suppression and tumor growth control.*
- •Proton Pump Inhibitors (PPIs)
- *Cost*: - Esomeprazole IV (40 mg/day × 7 days): $42–$68 - Oral maintenance (40 mg BID × 30 days): $28–$45
- •Somatostatin Analogues (SSAs)
- *Cost*: - Octreotide LAR (30 mg IM, monthly × 3 doses): $1,120–$1,480 - Lanreotide Autogel (120 mg IM, monthly × 3 doses): $1,260–$1,650
- •Supportive Lab/Monitoring (per 3-month cycle):
- Endoscopy + biopsy (if ulcer surveillance needed): $220–$340
Surgical / Interventional Options
*Eligibility: Localized, resectable primary tumor (duodenal/pancreatic), no distant metastasis on staging imaging.*
- •Preoperative Workup (mandatory):
- •Resection Procedures:
- Distal pancreatectomy (body/tail lesion): $7,200–$9,600 - Laparoscopic wedge resection (small duodenal lesion): $5,800–$7,500
- •Intraoperative ultrasound & frozen section confirmation included.
Special/Complex Condition Management
- •Metastatic (liver-dominant) disease:
- Peptide receptor radionuclide therapy (177Lu-DOTATATE, 4 cycles): $28,500–$34,200
- •Zollinger-Ellison syndrome with severe malabsorption:
- IV proton pump inhibition + nutritional support (7-day admission): $1,850–$2,400
Quick Selection Guide
- •<50 years, localized tumor, no comorbidities: Prioritize surgical resection — curative intent, lowest long-term cost.
- •≥65 years, multiple comorbidities (COPD, CAD), borderline resectable: Start with high-dose PPIs + SSA, defer surgery unless progressive.
- •Metastatic disease, good performance status: 177Lu-DOTATATE if DOTATATE-PET positive; otherwise TACE + SSA.
- •Budget-constrained (<$5,000 USD): PPI monotherapy + endoscopic surveillance — effective symptom control, avoids high-cost interventions.
- •Refractory hypergastrinemia with recurrent ulcers: Secretin-stimulated gastrin testing + EUS-guided FNA to confirm diagnosis before escalation.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Gastrinoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Gastrinoma treatment with China top medical destinations:
